1. Home
  2. IBTA vs ALLO Comparison

IBTA vs ALLO Comparison

Compare IBTA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ibotta Inc.

IBTA

Ibotta Inc.

HOLD

Current Price

$32.03

Market Cap

855.3M

Sector

N/A

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.95

Market Cap

738.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBTA
ALLO
Founded
2011
2017
Country
United States
United States
Employees
N/A
152
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
855.3M
738.4M
IPO Year
2024
2018

Fundamental Metrics

Financial Performance
Metric
IBTA
ALLO
Price
$32.03
$1.95
Analyst Decision
Hold
Strong Buy
Analyst Count
7
15
Target Price
$28.50
$8.35
AVG Volume (30 Days)
130.5K
6.9M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
$342,389,000.00
N/A
Revenue This Year
$2.02
N/A
Revenue Next Year
$8.96
$142,416.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.10
$0.99
52 Week High
$55.63
$4.46

Technical Indicators

Market Signals
Indicator
IBTA
ALLO
Relative Strength Index (RSI) 44.29 37.17
Support Level $21.23 $1.85
Resistance Level $35.11 $2.71
Average True Range (ATR) 2.08 0.14
MACD -0.85 -0.02
Stochastic Oscillator 29.26 11.22

Price Performance

Historical Comparison
IBTA
ALLO

About IBTA Ibotta Inc.

Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Share on Social Networks: